Literature DB >> 21319592

Risk factors of acute exacerbation of idiopathic pulmonary fibrosis.

Y Kondoh1, H Taniguchi, T Katsuta, K Kataoka, T Kimura, O Nishiyama, K Sakamoto, T Johkoh, M Nishimura, K Ono, M Kitaichi.   

Abstract

BACKGROUND: Although acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is a well known clinical condition, predicting risk factors remain unknown. We evaluated the frequency, risk factors and impact on survival of AE-IPF.
METHODS: We retrospectively studied patients diagnosed with IPF based on the criteria of the ATS/ERS consensus statement and followed them for periods of more than 3 years except in dead cases. Initial characteristics including the level of dyspnoea, which was assessed with the modified Medical Research Council (MRC) scale, and decline of forced vital capacity (FVC) defined by at least 10% decline at 6 months, were evaluated as possible risk factors for AE.
RESULTS: Seventy-four patients with IPF were studied. One-year, two-year, and three-year incidence of AE were 8.6%, 12.6%, and 23.9%, respectively. Multivariate analysis revealed that higher body mass index (BMI) [hazard ratio (HR), 1.20; 95% confidence interval (CI), 1.03-1.40], higher modified MRC scale [HR, 2.93; 95% CI, 1.46-5.85], and a decline in FVC at 6 mounths [HR, 0.97-2.60 (per mo); 95% CI, 1.01-7.45] were independent risk factors for AE-IPF. The causes of death were assessed to be AE in 20 of 57 expired patients. A stepwise multivariate Cox regression model evaluating AE-IPF, adjusted for %FVC and decline in FVC, demonstrated a statistically significant impact on overall survival [HR, 2.79; 95% CI, 1.59-4.88; p < 0.001].
CONCLUSION: These data suggest that initial high modified MRC scale, high BMI, and decline in FVC at 6 months were significant independent risk factors for AE-IPF. AE was an independent prognostic factor in IPF.

Entities:  

Mesh:

Year:  2010        PMID: 21319592

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  59 in total

1.  Acute exacerbation of idiopathic interstitial pneumonia after nonpulmonary surgery under general anesthesia: a retrospective study.

Authors:  Kenta Furuya; Susumu Sakamoto; Yujiro Takai; Nobukazu Sato; Keiko Matsumoto; Sakae Homma
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature.

Authors:  Andreina Manfredi; Marco Sebastiani; Stefania Cerri; Caterina Vacchi; Roberto Tonelli; Giovanni Della Casa; Giulia Cassone; Amelia Spinella; Pancaldi Fabrizio; Fabrizio Luppi; Carlo Salvarani
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

3.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Proposal.

Authors:  Kerri Johannson; Harold R Collard
Journal:  Curr Respir Care Rep       Date:  2013-12

Review 4.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

Authors:  Tomoo Kishaba
Journal:  Eurasian J Med       Date:  2017-10

5.  Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium.

Authors:  C Rinciog; A Diamantopoulos; A Gentilini; B Bondue; C Dahlqvist; A Froidure; W A Wuyts; S Soulard
Journal:  Pharmacoecon Open       Date:  2020-09

Review 6.  Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.

Authors:  Maya M Juarez; Andrew L Chan; Andrew G Norris; Brian M Morrissey; Timothy E Albertson
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

7.  Clinical and molecular features of rapidly progressive chronic hypersensitivity pneumonitis.

Authors:  Yasushi Horimasu; Nobuhisa Ishikawa; Hiroshi Iwamoto; Shinichiro Ohshimo; Hironobu Hamada; Noboru Hattori; Morihito Okada; Koji Arihiro; Yuji Ohtsuki; Nobuoki Kohno
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

8.  A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.

Authors:  C Rinciog; M Watkins; S Chang; T M Maher; C LeReun; D Esser; A Diamantopoulos
Journal:  Pharmacoeconomics       Date:  2017-04       Impact factor: 4.981

9.  Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis.

Authors:  Naohiro Watanabe; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Osamu Nishiyama; Masashi Kondo; Yoshinori Hasegawa
Journal:  Int J Clin Oncol       Date:  2013-04-17       Impact factor: 3.402

10.  A retrospective study of prognostic factors in patients with interstitial pneumonia receiving long-term oxygen therapy.

Authors:  Masayoshi Higashiguchi; Takashi Kijima; Hiromitsu Sumikawa; Osamu Honda; Toshiyuki Minami; Haruhiko Hirata; Koji Inoue; Izumi Nagatomo; Yoshito Takeda; Hiroshi Kida; Noriyuki Tomiyama; Atsushi Kumanogoh
Journal:  Lung       Date:  2014-07-24       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.